Toyota|$17.93 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.65 (¥3,889)-1.72%▼ (in JPY terms)
SoftBank|$29.91 (¥4,718)+0.77%▲ (in JPY terms)
MUFG|$21.77 (¥3,435)+1.72%▲ (in JPY terms)
Keyence|$492.08 (¥77,630)-1.97%▼ (in JPY terms)
Nintendo|$51.83 (¥8,176)-1.62%▼ (in JPY terms)
NTT|$1.08 (¥171)-0.64%▼ (in JPY terms)
Takeda|$40.55 (¥6,397)+1.43%▲ (in JPY terms)
Tokyo Electron|$62.43 (¥9,849)+0.45%▲ (in JPY terms)
Recruit|$119.58 (¥18,865)+0.35%▲ (in JPY terms)
ITOCHU|$14.57 (¥2,299)-0.54%▼ (in JPY terms)
Honda|$11.19 (¥1,765)+0.14%▲ (in JPY terms)
Shin-Etsu|$37.94 (¥5,985)-0.32%▼ (in JPY terms)
Tokio Marine|$3.57 (¥564)+1.57%▲ (in JPY terms)
Fast Retailing|$465.14 (¥73,380)-0.19%▼ (in JPY terms)
Toyota|$17.93 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.65 (¥3,889)-1.72%▼ (in JPY terms)
SoftBank|$29.91 (¥4,718)+0.77%▲ (in JPY terms)
MUFG|$21.77 (¥3,435)+1.72%▲ (in JPY terms)
Keyence|$492.08 (¥77,630)-1.97%▼ (in JPY terms)
Nintendo|$51.83 (¥8,176)-1.62%▼ (in JPY terms)
NTT|$1.08 (¥171)-0.64%▼ (in JPY terms)
Takeda|$40.55 (¥6,397)+1.43%▲ (in JPY terms)
Tokyo Electron|$62.43 (¥9,849)+0.45%▲ (in JPY terms)
Recruit|$119.58 (¥18,865)+0.35%▲ (in JPY terms)
ITOCHU|$14.57 (¥2,299)-0.54%▼ (in JPY terms)
Honda|$11.19 (¥1,765)+0.14%▲ (in JPY terms)
Shin-Etsu|$37.94 (¥5,985)-0.32%▼ (in JPY terms)
Tokio Marine|$3.57 (¥564)+1.57%▲ (in JPY terms)
Fast Retailing|$465.14 (¥73,380)-0.19%▼ (in JPY terms)

SUMITOMO CHEMICAL COMPANY,LIMITED “We have released a YouTube video titled "A Close Look at Our Employees' Challenges! ~[A Day in the Life] Taking on Diseases That Couldn't Be Cured with Conventional Medicines! The Challenges of Oligonucleotide Department Members Supporting Cutting-Edge Pharmaceutical Development~".”

SUMITOMO CHEMICAL COMPANY,LIMITED “We have released a YouTube video titled "A Close Look at Our Employees' Challenges! ~[A Day in the Life] Taking on Diseases That Couldn't Be Cured with Conventional Medicines! The Challenges of Oligonucleotide Department Members Supporting Cutting-Edge Pharmaceutical Development~".”

AI-Generated Summary

Sumitomo Chemical is highlighting its oligonucleotide drug development capabilities through employee-focused content, signaling management’s commitment to positioning the company as an innovator in next-generation pharmaceuticals for previously intractable diseases. This marketing initiative suggests the company views its oligonucleotide platform as a material growth driver and is investing in employer branding to attract talent in this strategically important research area.

This summary is AI-generated based on the release title and may not reflect the full content of the original document.

コメントする